Published in Immunity on August 01, 2003
HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol (2006) 1.41
HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat Immunol (2010) 1.38
HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol (2012) 1.25
Conformational lability in the class II MHC 310 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange. Proc Natl Acad Sci U S A (2011) 1.23
Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat Immunol (2009) 1.22
Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell (2012) 1.21
Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association. J Biol Chem (2007) 1.16
Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol (2006) 1.10
Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes. J Immunol (2009) 1.10
Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM. J Immunol (2008) 1.10
An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations. J Immunol (2011) 1.04
Conformational variation in structures of classical and non-classical MHCII proteins and functional implications. Immunol Rev (2012) 1.00
The convergent roles of tapasin and HLA-DM in antigen presentation. Trends Immunol (2008) 0.99
HLA-DM mediates epitope selection by a "compare-exchange" mechanism when a potential peptide pool is available. PLoS One (2008) 0.97
Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proc Natl Acad Sci U S A (2012) 0.97
Comprehensive analysis of MHC class II genes in teleost fish genomes reveals dispensability of the peptide-loading DM system in a large part of vertebrates. BMC Evol Biol (2013) 0.97
On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Expert Rev Mol Med (2012) 0.95
The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway. Curr Opin Immunol (2011) 0.95
In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol (2009) 0.93
A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM. Proc Natl Acad Sci U S A (2005) 0.92
HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation. Curr Opin Immunol (2013) 0.92
DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms. Immunology (2010) 0.91
HLA-DO and Its Role in MHC Class II Antigen Presentation. Front Immunol (2013) 0.90
Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunol Res (2010) 0.90
Mechanisms of peptide repertoire selection by HLA-DM. Trends Immunol (2013) 0.89
HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol (2009) 0.88
The control of the specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings. Front Immunol (2013) 0.87
Three-dimensional structure determines the pattern of CD4+ T-cell epitope dominance in influenza virus hemagglutinin. J Virol (2007) 0.87
Accelerated turnover of MHC class II molecules in nonobese diabetic mice is developmentally and environmentally regulated in vivo and dispensable for autoimmunity. J Immunol (2013) 0.83
Flanking p10 contribution and sequence bias in matrix based epitope prediction: revisiting the assumption of independent binding pockets. BMC Struct Biol (2008) 0.82
Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions. J Immunol (2015) 0.81
Pulse-chase analysis for studies of MHC class II biosynthesis, maturation, and peptide loading. Methods Mol Biol (2013) 0.81
The MHC class II cofactor HLA-DM interacts with Ig in B cells. J Immunol (2014) 0.80
Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DObeta. Immunology (2008) 0.79
A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination. J Immunol Methods (2014) 0.79
An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. PLoS One (2014) 0.77
Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules. Immunology (2010) 0.77
HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange. Front Immunol (2013) 0.77
pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity. Sci Rep (2015) 0.76
A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells. F1000Res (2016) 0.76
Structural Insights Into HLA-DM Mediated MHC II Peptide Exchange. Curr Top Biochem Res (2011) 0.76
Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol (2017) 0.75
Human leukocyte Antigen-DM polymorphisms in autoimmune diseases. Open Biol (2016) 0.75
The Other Function: Class II-Restricted Antigen Presentation by B Cells. Front Immunol (2017) 0.75
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol (2011) 2.88
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Retracted CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med (2013) 2.51
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol (2012) 2.47
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev (2005) 1.74
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer (2012) 1.70
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One (2010) 1.69
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci (2007) 1.62
Precarious balance: Th17 cells in host defense. Infect Immun (2009) 1.60
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis. J Immunol (2011) 1.56
T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity (2009) 1.50
Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol (2003) 1.44
Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J Biol Chem (2007) 1.44
Role of pediatric and internist rheumatologists in treating children with rheumatic diseases. Pediatrics (2004) 1.39
Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Clin Cancer Res (2012) 1.39
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res (2013) 1.38
Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer (2012) 1.31
Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol (2009) 1.27
HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol (2012) 1.25
Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol (2008) 1.24
Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol (2010) 1.20
Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol (2002) 1.14
Labeling antigen-specific CD4(+) T cells with class II MHC oligomers. J Immunol Methods (2002) 1.11
Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol (2009) 1.11
Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology (2009) 1.11
Selective developmental defects of cord blood antigen-presenting cell subsets. Hum Immunol (2004) 1.09
Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol (2006) 1.06
Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol (2002) 1.05
Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol (2009) 1.05
DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci U S A (2006) 1.04
An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations. J Immunol (2011) 1.04
Measurement of very low rates of cell proliferation by heavy water labeling of DNA and gas chromatography/pyrolysis/isotope ratio-mass spectrometric analysis. Nat Protoc (2007) 1.04
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery. J Neurosci Res (2007) 1.00
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.99
Measurement of protein synthesis using heavy water labeling and peptide mass spectrometry: Discrimination between major histocompatibility complex allotypes. Anal Biochem (2010) 0.99
Urine peptidomics for clinical biomarker discovery. Adv Clin Chem (2010) 0.99
In vivo measurement of microtubule dynamics using stable isotope labeling with heavy water. Effect of taxanes. J Biol Chem (2004) 0.99
Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum (2012) 0.98
Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proc Natl Acad Sci U S A (2012) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism. J Immunol (2003) 0.97
Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics (2010) 0.96
Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J Immunol (2003) 0.96
On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Expert Rev Mol Med (2012) 0.95
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer (2013) 0.95
Self-antigen recognition by follicular lymphoma B-cell receptors. Blood (2012) 0.95
Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique. J Pharmacol Exp Ther (2006) 0.94
Human cytomegalovirus alters localization of MHC class II and dendrite morphology in mature Langerhans cells. J Immunol (2006) 0.94
Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers. J Immunol Methods (2002) 0.94
Access to pediatric rheumatology care in the United States. Arthritis Rheum (2003) 0.93
Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis. Clin Proteomics (2010) 0.93
Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. Arthritis Rheum (2013) 0.93
Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer (2013) 0.92
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol (2012) 0.92
Medicine on a need-to-know basis. Nat Immunol (2006) 0.92
Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol (2006) 0.92
Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels. Mol Immunol (2011) 0.92
Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum (2008) 0.92
DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms. Immunology (2010) 0.91
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM. Biochemistry (2003) 0.90
Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood (2002) 0.90
Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. Breast Cancer Res Treat (2012) 0.89
Cathepsin G: roles in antigen presentation and beyond. Mol Immunol (2009) 0.89
Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways. Blood (2011) 0.88
Bordetella pertussis infection of primary human monocytes alters HLA-DR expression. Infect Immun (2004) 0.87
Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book (2013) 0.87
Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin Immunol (2010) 0.86
A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med (2012) 0.85
I-Ag7 is subject to post-translational chaperoning by CLIP. Int Immunol (2010) 0.85
Influenza A virus elevates active cathepsin B in primary murine DC. Int Immunol (2007) 0.84
Accelerated turnover of MHC class II molecules in nonobese diabetic mice is developmentally and environmentally regulated in vivo and dispensable for autoimmunity. J Immunol (2013) 0.83
Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol (2011) 0.83
Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J (2008) 0.83
Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus. Pediatr Rheumatol Online J (2008) 0.82
Posttranslational regulation of I-Ed by affinity for CLIP. J Immunol (2007) 0.82
Pulse-chase analysis for studies of MHC class II biosynthesis, maturation, and peptide loading. Methods Mol Biol (2013) 0.81
A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS One (2012) 0.81
The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome. BMC Musculoskelet Disord (2014) 0.80
Cytokines elicited by T cell epitopes from a synovial autoantigen: altered peptide ligands can reduce interferon-gamma and interleukin-10 production. Arthritis Rheum (2003) 0.79
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol (2013) 0.79
Host-derived CD4+ T cells attenuate stem cell-mediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. Arthritis Rheum (2013) 0.79
Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol (2011) 0.78